What is Complix?
Complix is a biopharmaceutical company specializing in the development of transformative Cell Penetrating Alphabody (CPAB) therapeutics. Their proprietary technology is designed to address previously undruggable intracellular targets associated with severe diseases, including cancer and autoimmune disorders. The company's platform offers innovative delivery methods, potentially including non-injectable options, aiming to expand the reach of biopharmaceuticals. Complix is actively building a pipeline of product candidates and is open to strategic partnerships to further leverage its Alphabody platform's potential.
How much funding has Complix raised?
Complix has raised a total of $22.3M across 3 funding rounds:
Series A
$6.2M
Series B
$15.5M
Grant
$600K
Series A (2010): $6.2M with participation from Lrm, Vesalius Biocapital Partners, and CRP Sante
Series B (2013): $15.5M led by Vesalius Biocapital Partners, Edmond de Rothschild Investment Partners, Gimv, OMNES Capital, CRP-Sante, Baekeland Fund, and TrustCapital
Grant (2017): $600K, investors not publicly disclosed
Key Investors in Complix
Vesalius Biocapital Partners
Vesalius Biocapital Partners is a venture capital firm that invests in innovative European life science companies, with a focus on human health. They invest across all development stages, particularly favoring early-stage projects with strong proprietary technology and unique team skills, emphasizing therapeutics, medical devices, and diagnostics.
Edmond de Rothschild Investment Partners
Edmond de Rothschild is an investment banking firm offering a range of financial services and solutions, with a history dating back to 1923 and headquartered in France.
CRP Sante
CRP-Santé operates within the Research & Development industry in Luxembourg, focusing on advancing scientific and technological innovation.
What's next for Complix?
With the recent major strategic investment and substantial enterprise-level funding, Complix is well-positioned to accelerate the development of its CPAB therapeutic pipeline. The company's focus on targeting difficult intracellular disease mechanisms, particularly in oncology and immunology, suggests a strategic push towards clinical validation and potential commercialization. Future endeavors will likely involve advancing existing product candidates through further research and development phases, potentially seeking additional collaborations or partnerships to enhance the platform's therapeutic applications and market penetration.
See full Complix company page
